"hepatitis c virus cure" blog posts
Community engagement – shaping the long-acting technologies pipeline
The latest World Health Organisation (WHO) reports estimate 58 million people globally have chronic hepatitis C virus (HCV) infection, with about 1.5 million new infections occurring per year. 75% of these cases occur in low- and middle-income countries. It is estimated that oral drugs at the point of diagnosis provide a 98% cure rate if an entire oral regimen is completed. However, in LMICs, access to medication can be complex with issues around stigma and pill burden resulting in poor completion rates.
Posted on: 28 July 2022
Developing a single-injection cure for hepatitis C virus for low- and middle-income countries
Dr. David Lee Thomas is a professor of medicine at the Johns Hopkins University School of Medicine. He is trained in internal medicine and infectious diseases and cares for patients with chronic viral hepatitis. Dave leads the Hepatitis C programme for the Unitaid funded LONGEVITY project for CELT. From 2006-2022, Dr. Thomas served as the director of the Division of Infectious Diseases and the Stanhope Bayne-Jones Professor of Medicine. He remains a Professor of Medicine in the School of Medicine and of Epidemiology in the Bloomberg School of Public Health. He is a co-director of the Centre for AIDS Research Clinical Core. For world Hepatitis Day 2022, Dr Thomas shared his expertise on Hepatitis C virus as a world-leading clinical researcher.
Posted on: 28 July 2022